Navigation Links
MEI Pharma Adds Cancer Drug Development Veteran Tom Reynolds to Board of Directors
Date:2/11/2013

nd Ph.D. in Biophysics from Stanford University and a B.A. in Chemistry from Dartmouth College.

"I am delighted to join the Board of MEI Pharma at such an exciting time for the company," said Dr. Reynolds. "I believe that MEI Pharma is poised to make an immediate impact in the oncology arena with its lead drug candidate, Pracinostat. I look forward to working closely with the rest of the Board and management team to execute the optimal clinical development and marketing approval strategy for Pracinostat and ultimately realize its significant potential."

About MEI Pharma

MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral histone deacetylase (HDAC) inhibitor being developed for advanced hematologic malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with azacitidine in patients with advanced MDS were presented at the American Society of Hematology Annual Meeting in December 2012 showing an overall response rate (CR+CRi+PR) of 89% (eight out of nine). The Company plans to initiate a randomized, placebo-controlled Phase II trial of Pracinostat in combination with azacitidine in patients with MDS by June 2013. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nat
'/>"/>

SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. WuXi PharmaTech Announces Third-Quarter 2011 Results
3. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
4. Pharmasset Reports Fiscal Year End 2011 Financial Results
5. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
6. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
7. PRA Expert to Present at Pharmacovigilance Conference
8. Nutra Pharma Announces Publication of a New Mechanism Study of Alpha-Cobratoxin in the Treatment of Pain
9. InnoPharma Completes $15 Million Series A Financing
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. ViroPharma to Participate in Two December Healthcare Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar will ... and clinical safety assessment in biosimilars. , Regulatory frameworks ... biosimilar drug development, however the complex nature of biopharmaceuticals ... safety and efficacy extremely challenging. Based on the specific ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 DTS Language ... its Online Web Portal for Life Science organizations who need ... specify the subject matter of their documents in advance with ... help reduce time-to-delivery of translations, often a critical factor in ...
(Date:1/14/2014)... PA (PRWEB) January 14, 2014 Date: Friday, ... , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... national nonprofit organization solely dedicated to finding a cure for ... affected worldwide, will host its annual Crystal Ball on Friday, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... widely used as a navigational tool in vehicles from ... vehicle on three axes to evaluate its exact position ... School of Physical Engineering is now scaling down this ... and more futuristic technologies. Working in collaboration with ...
... 5 Regenicin™, Inc. (OTC Bulletin Board: ... announced today that Mr. Christopher A. Hadsall, whose primary ... to join the company as Chief Operating Officer.  Mr. ... Regenicin™ and will be instrumental in working with various ...
... MiMedx Group, Inc. (OTC Bulletin Board: ... patent protected biomaterial-based products, announced today that its results ... be released before the opening of the market on ... live broadcast of its third quarter conference call on ...
Cached Biology Technology:A tracking device that fits on the head of a pin 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 3MiMedx Group, Inc. Announces Release Date For Third Quarter Results 2
(Date:4/23/2014)... of Toronto Scarborough research shows that male black widow ... a rare example of mate preference by male ... post-doc Emily MacLeod and Maydianne Andrade, a professor in ... field studies and the wild that males overwhelmingly chose ... male black widows can tell whether a potential mate ...
(Date:4/23/2014)... Putnam Valley, NY. (Apr. 23, 2014) People who ... little potential to restore neurological function. However, a study ... future issue of Cell Transplantation , but is ... at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct1168Chen , has found that when one ... stem cells (PBSCs) injected directly into the brain and ...
(Date:4/23/2014)... boom has transformed the energy landscape in the ... cause conflict among the energy industry, residents and ... They add that degraded water quality is a ... feature article appears in the ACS journal ... Mauter and colleagues point out that a major ...
Breaking Biology News(10 mins):Picky male black widow spiders prefer well-fed virgins 2Autologous stem cell therapy improves motor function in chronic stroke victims 2How to avoid water wars between 'fracking' industry and residents 2
... scientist Dr. Gadi V.P. Reddy is concerned about ... health of island residents and ecosystems. He has ... use and has recently been awarded an $188,000 ... (USDA-NIFA) Pest Management Alternatives Program (PMAP). Dr. Monte ...
... PA, June 24, 2011 Adolescents who diet and ... behaviors and binge eating) carry these unhealthy practices into ... by University of Minnesota researchers and published in the ... American Dietetic Association . "The findings from the ...
... applications in reconstructive and cosmetic surgery and in the food ... prolines within the protein need to be hydroxylated. BioMed Central,s ... the first time the α1 chain of type 1 collagen ... hydroxylation to human collagen. Most collagen used is derived ...
Cached Biology News:UOG scientist wins USDA competitive funding 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 2Adolescents' dieting and disordered eating behaviors continue into young adulthood 3